Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.30−0.20 (-3.64%)
Close on Nov 18, 2026Market cap $430.85MP/E –Yield –
Phathom Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Phathom Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was -$21.04M. For fiscal 2025 it was -$167.00M. The highest annual figure on record is -$36.64M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$167.00M | – |
| FY2024 | Dec 31, 2024 | -$266.91M | – |
| FY2023 | Dec 31, 2023 | -$139.21M | – |
| FY2022 | Dec 31, 2022 | -$147.57M | – |
| FY2021 | Dec 31, 2021 | -$148.79M | – |
| FY2020 | Dec 31, 2020 | -$70.73M | – |
| FY2019 | Dec 31, 2019 | -$36.64M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.73M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.71M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$62.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$84.95M | – |
| Q4 FY2024 | Dec 31, 2024 | -$63.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$63.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$70.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$44.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.85M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$41.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.14M | – |
| Q1 FY2022 | Mar 31, 2022 | -$44.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$41.36M | – |
| Q3 FY2021 | Sep 30, 2021 | -$29.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.41M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.40M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.09M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.49M | – |
See a number that looks wrong?